In Vitro Skin Sensitization: Assessing the Risk of Allergic Contact Dermatitis Without the Use of Animals

Allergic contact dermatitis is an immune-mediated, delayed-type hypersensitivity reaction that develops in response to chemical substances. Once sensitized, an individual may develop a severe reaction even upon re-exposure to very low concentrations. Therefore, determining the potential for skin sensitization is a critical step in the safety assessment of chemicals, cosmetic ingredients, pesticides, and medical devices. In vitro skin sensitization tests enable this assessment to be conducted without the use of animals, using validated methods and in accordance with international standards.

Why In Vitro Skin Sensitization?

Traditional sensitization tests (Guinea Pig Maximization Test, Buehler Test, Local Lymph Node Assay) require the use of animals, and protocols involving adjuvants, in particular, raise serious animal welfare concerns. In contrast, in vitro and in chemico methods are ethically superior because they use human cell lines and synthetic peptides; they offer high reproducibility and allow for more direct extrapolation to human biology.

They also hold significant regulatory weight. Data obtained using these methods are valid under the EU REACH and CLP Regulations; under the EU Cosmetics Regulation (EC 1223/2009), since animal testing is prohibited for cosmetic products and ingredients, in vitro methods are the only mandatory option. For medical devices, the ISO 10993-10 standard mandates the evaluation of sensitization for devices that come into contact with the skin and explicitly refers to validated in vitro methods.

Adverse Outcome Pathway (AOP) and Three Key Events

Skin sensitization proceeds via a defined biological pathway, which has been modeled as the Adverse Outcome Pathway (AOP). The pathway consists of three key events (KE):

KE1 – Protein binding (haptenation): Electrophilic sensitizers form covalent bonds with nucleophilic residues (cysteine, lysine) on skin proteins. This event is measured using OECD TG 442C (DPRA), a chemico method.

KE2 – Keratinocyte activation: As a result of haptenation, antioxidant/cytoprotective response pathways (particularly Nrf2-ARE) are activated in keratinocytes, and inflammatory cytokines are released. This event is measured using OECD TG 442D (KeratinoSens™).

KE3 – Dendritic cell activation: Langerhans cells mature, increasing their surface markers (CD54, CD86), and present antigens to T lymphocytes. This event is measured using the methods described in OECD TG 442E (h-CLAT, U-SENS™, IL-8 Luc).

Since each test evaluates a different link in the chain of events, no single test is sufficient on its own to determine sensitization potential. Therefore, the OECD has developed defined approaches that call for the combined interpretation of the tests.

Three Validated Methods

OECD TG 442C (DPRA – Direct Peptide Reactivity Assay) is based on measuring the decrease in peptides via HPLC following incubation of the test substance with peptides containing synthetic cysteine and lysine. It is rapid and economical; however, it is not suitable for metal compounds and substances with oxidative properties.

OECD TG 442D (KeratinoSens™) uses a human keratinocyte cell line expressing a luciferase reporter gene that tracks the Nrf2-ARE pathway. Imax and EC1.5 values are calculated by measuring luciferase induction following exposure to the test substance. Results falling within the indeterminate range should be interpreted in conjunction with other tests.

OECD TG 442E (h-CLAT, U-SENS™, IL-8 Luc) measures increased expression of the surface markers CD54 and CD86 or IL-8 release in human monocyte/dendritic cell-like cell lines. For highly lipophilic substances (Log P > 3.5), the reliability of negative results may be limited; this should be taken into account when interpreting the results.

The table below provides a comparative summary of the key characteristics of the three methods.

Comparison of In Vitro Skin Sensitization Methods
Characteristic TG 442C (DPRA) TG 442D (KeratinoSens™) TG 442E (h-CLAT)
AOP Key Event KE1 – Protein binding KE2 – Keratinocyte activation KE3 – Dendritic cell activation
Test System Synthetic peptides (in chemico) HaCaT keratinocyte reporter cell line THP-1 monocyte cell line
Measurement Parameter Peptide depletion (HPLC, %) Luciferase induction (Imax, EC1.5) Increase in CD54/CD86 expression (RFI)
Key Limitations Not suitable for metal compounds and oxidizing agents Additional interpretation required in uncertain ranges Negative results for compounds with Log P > 3.5 have limited reliability
3R Compliance Full Full Full

2o3 Defined Approach and Interpretation of Results

The 2o3 DA aims to determine sensitization potential without using animals by combining the results of three tests. The basic interpretation rule is as follows: If at least two of the three tests are positive, the substance is classified as a “sensitizer”; if at least two are negative, it is classified as “not a sensitizer.” If one of the results falls within an indeterminate range or if structural limitations of the tests come into play, the DA result may be “indeterminate”; in this case, additional information (chemical characterization, in silico modeling, or in vivo validation) may be required.

Results are classified according to GHS criteria. Category 1 indicates that the substance has the potential to cause an allergic reaction following skin contact; it is labeled with the statement “May cause an allergic skin reaction” (H317) and the GHS07 pictogram. Subcategory 1A defines strong sensitizers, while subcategory 1B defines weak/moderate sensitizers. Substances that do not demonstrate sensitization potential based on available data are not classified.

The table below summarizes the rules for interpreting 2o3 DA results and their corresponding classifications.

Interpretation of 2o3 DA Results and GHS Equivalents
Test Results (DPRA / KeratinoSens™ / h-CLAT) DA Result GHS Classification Recommended Next Step
At least two tests are positive Sensitizer Category 1 (H317) Labeling and risk management measures
At least two tests are negative Not a sensitizer Unclassified Evaluation is complete
One test is inconclusive, the other two are consistent Inconclusive No conclusion can be drawn Chemical characterization, in silico or in vivo validation
Inconsistency among tests Indeterminate No conclusion can be drawn Additional information and expert assessment

Regulatory Framework

Under the EU REACH and CLP Regulations, in vitro sensitization data are valid for chemical safety assessment and classification. Under the EU Cosmetics Regulation (EC 1223/2009), since animal testing is prohibited, validated in vitro methods and defined approaches are the only mandatory option for cosmetic products. ISO 10993-10 requires sensitization assessment for medical devices in contact with the skin; the standard refers to GPMT, Buehler, and LLNA, as well as validated in vitro methods. Cosmetic regulations also stipulate requirements aligned with the EU framework.

In terms of labeling, the H317 statement and the GHS07 pictogram are mandatory for a substance classified as a sensitizer; furthermore, appropriate precautionary statements (P261, P272, P280, P333+P313) must be included in the safety data sheet. These requirements form the basis for risk management in both occupational and consumer use of the product.

Frequently Asked Questions

Which test combination is suitable for my product? 2o3 DA is generally sufficient for substances that are highly soluble, metal-free, and have a Log P value below 3.5. For substances with solubility issues, UVCB substances, or complex mixtures, DA may yield “indeterminate” results; in such cases, additional information is required.
Our laboratory recommends the most appropriate strategy based on your product’s characteristics.

Do in vitro results substitute for in vivo testing? Validated in vitro methods and 2o3 DA allow for classification without the need for in vivo testing. The OECD and EU REACH recognize these methods as primary tests. In cases where results are inconclusive or when specifically requested by the regulatory authority, in vivo validation may be required.

Which standard applies to medical devices? A sensitization assessment under ISO 10993-10 is mandatory for medical devices that come into contact with the skin. Extracts prepared from the device in accordance with ISO 10993-12 are tested using appropriate methods; the testing strategy is determined based on the device’s contact duration and type.

For which applications can the reports be used? Our reports are valid for registration and classification dossiers under the EU REACH and CLP regulations, product safety reports under the EU Cosmetics Regulation, and biocompatibility dossiers under ISO 10993-10.

Contact our laboratory to assess your product’s sensitization potential using validated in vitro methods, in accordance with GLP standards, and without the need for animal testing. Our team of experts will determine a test strategy tailored to your product, thereby accelerating your regulatory process.

EnglishenEnglishEnglish